{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:29:10Z","timestamp":1790648950801,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd005353.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2011,3,16]],"date-time":"2011-03-16T00:00:00Z","timestamp":1300233600000}}],"reference-count":36,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005353.pub4","type":"journal-article","created":{"date-parts":[[2011,3,9]],"date-time":"2011-03-09T22:44:33Z","timestamp":1299710673000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Cannabinoid type 1 receptor antagonists for smoking cessation"],"prefix":"10.1002","volume":"2012","author":[{"given":"Kate","family":"Cahill","sequence":"first","affiliation":[{"name":"University of Oxford; Department of Primary Care Health Sciences; 23-38 Hythe Bridge Street Oxford UK OX1 2ET"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H","family":"Ussher","sequence":"additional","affiliation":[{"name":"St George's, University of London; Division of Population Health Sciences and Education; Cranmer Terrace London UK SW17 0RE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,3,16]]},"reference":[{"key":"10.1002\/14651858.CD005353.pub4-BIB0001|cit1","unstructured":"Cinciripini PM Aubin H-J Dale LC Niaura R Anthenelli RM Robinson J Pooled analysis of three short-term, randomised, double-blind, placebo-controlled trials with rimonabant 20 mg\/d in smoking cessation [PI-TS-01] Society for Research on Nicotine and Tobacco 8th European Conference, September 2006, Kusadasi Turkey 2006"},{"key":"10.1002\/14651858.CD005353.pub4-BIB0002|cit2","unstructured":"Sanofi Aventis Information Meeting http:\/\/en.sanofi-aventis.com\/Images\/en_050301_up_2004_Full_Year_Results_Analysts_Investors_meeting_in_Paris_presentation_tcm24-3612.pdf (accessed 23rd November 2006) 2005"},{"key":"10.1002\/14651858.CD005353.pub4-BIB0003|cit3","unstructured":"Anthenelli RM Depres J-P Effects of rimonabant in the reduction of major cardiovascular risk factors. Results from the STRATUS-US Trial (smoking cessation in smokers motivated to quit) and the RIO-LIPIDS Trial (weight reducing and metabolic effects in overweight\/obese patients with dyslipidemia American College of Cardiology Annual Scientific Session March 2004"},{"key":"10.1002\/14651858.CD005353.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1345\/aph.1E499","article-title":"Rimonabant - a selective CB1 antagonist","volume":"39","author":"Boyd","year":"2005","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD005353.pub4-BIB0005|cit5","unstructured":"Cinciripini PM Aubin H-J Dale LC Niaura R Anthenelli RM Robinson J Pooled analysis of three short-term, randomised, double-blind, placebo-controlled trials with rimonabant 20 mg\/d in smoking cessation [PI-TS-01] Society for Research on Nicotine and Tobacco 8th European Conference, September 2006, Kusadasi Turkey 2006"},{"key":"10.1002\/14651858.CD005353.pub4-BIB0006|cit6","article-title":"Long-term maintenance of abstinence from smoking with rimonabant: results from the STRATUS Worldwide trial. 1-year efficacy\/safety results","author":"Niaura","year":"2005","journal-title":"American Thoracic Society Conference"},{"key":"10.1002\/14651858.CD005353.pub4-BIB0007|cit7","unstructured":"Niaura R Long-term maintenance of abstinence from smoking with rimonabant: results from the STRATUS Worldwide trial. 6-month efficacy\/safety results [POS1-054] American Thoracic Society Conference 2004"},{"key":"10.1002\/14651858.CD005353.pub4-BIB0008|cit8","unstructured":"Sanofi Aventis Information Meeting http:\/\/en.sanofi-aventis.com\/Images\/en_050301_up_2004_Full_Year_Results_Analysts_Investors_meeting_in_Paris_presentation_tcm24-3612.pdf (accessed 23rd November 2006) 2005"},{"key":"10.1002\/14651858.CD005353.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00213-010-1790-2","article-title":"Randomized, controlled, double-blind trial of taranabant for smoking cessation","volume":"209","author":"Morrison","year":"2010","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD005353.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1360-0443.2008.02454.x","article-title":"A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain","volume":"104","author":"Rigotti","year":"2009","journal-title":"Addiction"},{"issue":"2","key":"10.1002\/14651858.CD005353.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1360-0443.2008.02487.x","article-title":"Trial comes too late as psychiatric side effects end hope for rimonabant","volume":"104","author":"Stapleton","year":"2009","journal-title":"Addiction"},{"key":"10.1002\/14651858.CD005353.pub4-BIB0012|cit12","unstructured":"Cinciripini PM Aubin H-J Dale LC Niaura R Anthenelli RM Robinson J Pooled analysis of three short-term, randomised, double-blind, placebo-controlled trials with rimonabant 20 mg\/d in smoking cessation [PI-TS-01] Society for Research on Nicotine and Tobacco 8th European Conference, September 2006, Kusadasi Turkey 2006"},{"key":"10.1002\/14651858.CD005353.pub4-BIB0013|cit13","article-title":"Comparison of efficacy and safety of rimonabant 20mg\/day versus placebo in smoking cessation","author":"Sanofi","year":"2007","journal-title":"http:\/\/clinicaltrials.gov\/show\/NCT00464256 (accessed 17th October 2007)"},{"issue":"9740","key":"10.1002\/14651858.CD005353.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(10)60935-X","article-title":"Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial","volume":"376","author":"Topol","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005353.pub4-BIB0015|cit15","unstructured":"American College of Cardiology Data shows new drug, rimonabant, helps smokers quit while limiting post cessation weight gain www.eurekalert.org\/pub_releases\/2004-03\/k-dsn030904.php"},{"key":"10.1002\/14651858.CD005353.pub4-BIB0016|cit16","unstructured":"Sanofi-Aventis Acomplia 20mg Summary of Product Characteristics http:\/\/emc.medicines.org.uk\/emc\/assets\/c\/html\/displaydoc.asp?documentid=18283 (accessed 18th April 2007) 2006"},{"issue":"5","key":"10.1002\/14651858.CD005353.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/ijo.2010.21","article-title":"A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study","volume":"34","author":"Aronne","year":"2010","journal-title":"International Journal of Obesity"},{"key":"10.1002\/14651858.CD005353.pub4-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ejheart.2004.04.014","article-title":"Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-LIPIDS and cardiac resynchronisation therapy in heart failure","volume":"6","author":"Cleland","year":"2004","journal-title":"European Journal of Heart Failure"},{"key":"10.1002\/14651858.CD005353.pub4-BIB0019|cit19","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006] http:\/\/www.cochrane.org\/resources\/handbook\/hbook.htm (accessed 18th April 2007) 2006"},{"issue":"4","key":"10.1002\/14651858.CD005353.pub4-BIB0020|cit20","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006162.pub2","article-title":"Rimonabant for overweight or obesity","author":"Curioni","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD005353.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1517\/13543784.15.2.107","article-title":"Neuropharmacology and potential efficacy of new treatments for tobacco dependence","volume":"15","author":"Fagerstr\u00f6m","year":"2006","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1002\/14651858.CD005353.pub4-BIB0022|cit22","unstructured":"Food Drug Administration Summary Minutes of the Endocrinologic and Metabolic Drugs Advisory Committee meeting on June 13, 2007 www.fda.gov\/ohrms\/dockets\/ac\/07\/minutes\/2007-4306m1-final.pdf (accessed 6th August 2007) 2007"},{"key":"10.1002\/14651858.CD005353.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1467-789X.2004.00131.x","article-title":"Smoking cessation and weight gain","volume":"5","author":"Filozof","year":"2004","journal-title":"Obesity Review"},{"issue":"10","key":"10.1002\/14651858.CD005353.pub4-BIB0024|cit24","first-page":"1116","article-title":"Taranabant, a novel cannabinoid type 1 receptor inverse agonist","volume":"9","author":"Fremming","year":"2008","journal-title":"Current Opinion in Investigational Drugs"},{"issue":"3","key":"10.1002\/14651858.CD005353.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1517\/13543784.15.3.307","article-title":"Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors","volume":"15","author":"Gelfand","year":"2006","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"1","key":"10.1002\/14651858.CD005353.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/1462220031000070552","article-title":"Measures of abstinence in clinical trials: issues and recommendations","volume":"5","author":"Hughes","year":"2003","journal-title":"Nicotine & Tobacco Research"},{"issue":"2","key":"10.1002\/14651858.CD005353.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1369-1600.2008.00113.x","article-title":"Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from preclinical and clinical studies","volume":"13","author":"Foll","year":"2008","journal-title":"Addiction Biology"},{"key":"10.1002\/14651858.CD005353.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/ije\/27.6.984","article-title":"Body mass decrease after initial gain following smoking cessation","volume":"27","author":"Mizoue","year":"1998","journal-title":"International Journal of Epidemiology"},{"issue":"9","key":"10.1002\/14651858.CD005353.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/oxfordjournals.aje.a009706","article-title":"Early and late weight gain following smoking cessation in the Lung Health Study","volume":"148","author":"O'Hara","year":"1998","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD005353.pub4-BIB0030|cit30","unstructured":"Office for National Statistics Smoking-related behaviour and attitudes http:\/\/www.dh.gov.uk\/assetRoot\/04\/06\/81\/56\/04068156.pdf"},{"issue":"4","key":"10.1002\/14651858.CD005353.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0740-5472(99)00085-9","article-title":"Short-term weight gain in abstaining women smokers","volume":"18","author":"Pomerleau","year":"2000","journal-title":"Journal of Substance Abuse and Treatment"},{"key":"10.1002\/14651858.CD005353.pub4-BIB0032|cit32","volume-title":"RIO and STRATUS Clinical Studies Guide","author":"Sanofi--Synthelabo","year":"2003"},{"key":"10.1002\/14651858.CD005353.pub4-BIB0033|cit33","unstructured":"Sanofi Aventis Acomplia update post EMEA recommendation http:\/\/en.sanofi-aventis.com\/binaries\/20081023_Acomplia_Update_presentation_tcm28-22428.pdf 2008"},{"key":"10.1002\/14651858.CD005353.pub4-BIB0034|cit34","unstructured":"Sanofi-Synthelabo Two pivotal studies indicate ACOMPLIA (rimonabant) offers a novel approach to cardiovascular risk management in overweight\/obese people and smokers http:\/\/es.sanofi-synthelabo.com\/press\/ppc_23804.asp"},{"key":"10.1002\/14651858.CD005353.pub4-BIB0035|cit35","unstructured":"US Public Health Service The health benefits of smoking cessation: A report of the Surgeon General DHHS Publication No CDC 90-8416 1990"},{"issue":"4","key":"10.1002\/14651858.CD005353.pub4-BIB0036|cit36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005353.pub3","article-title":"Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation","author":"Cahill","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD005353.pub4\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T16:36:52Z","timestamp":1725467812000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD005353.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Tobacco Addiction Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,3,16]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2012,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005353.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,16]]}}}